Compare Novo Nordisk A/S (NVO) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Remitly Global Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Remitly Global Inc trades at $23.93 (market cap $5.02B). The key difference: Novo Nordisk A/S is far larger — about 43.9× Remitly Global Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| NVO | RELY | |
|---|---|---|
Market Cap | $220.53B | $5.02B |
Sector | Health | Technology |
52-Week High | $71.70 | $25.23 |
52-Week Low | $35.29 | $12.20 |
Enterprise Value | $239.49B | $4.41B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
